CytoMed Therapeutics (GDTC) Income towards Parent Company (2022 - 2025)

CytoMed Therapeutics has reported Income towards Parent Company for 4 years, with the latest figure at $7.1 million in Q2 2025.

• Quarterly Income towards Parent Company fell 29.67% year-over-year to $7.1 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $7.1 million (down 29.67% YoY) and the FY2025 annual result came in at -$3.1 million, down 134.52% from the prior year.
• Income towards Parent Company eased to $7.1 million in Q2 2025 per GDTC's latest filing, from $10.2 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at $13.2 million in Q2 2023 and troughed at $104.0 in Q2 2022.
• A 4-year average of $7.6 million and a median of $8.7 million in 2024 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2023 and 2025: Income towards Parent Company soared 12663048.08% in 2023, then slipped 29.67% in 2025.
• Over 4 years, Income towards Parent Company stood at $104.0 in 2022, then jumped by 12663048.08% to $13.2 million in 2023, then fell by 22.84% to $10.2 million in 2024, then dropped by 29.67% to $7.1 million in 2025.
• According to Business Quant data, Income towards Parent Company over the past three periods registered $7.1 million, $10.2 million, and $13.2 million for Q2 2025, Q2 2024, and Q2 2023 respectively.